Humacyte opened lower at $0.59, compared with its previous close of $0.59. In the last trading session, the stock traded between $0.56 and $0.63. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Humacyte is now worth
$ 6.08
Resulting in a loss of
$ 93.92 (93.92%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
60%
Hold
40%
Sell
0%
Markets Today
Today's Change
+$0.00 (+0.73%)
Day High
$0.63
Day Low
$0.56
Day Open
$0.59
Prev Close
$0.59
Volume
50,45,094
1W Return
32.44%
1M Return
52.82%
3M Return
-16.29%
6M Return
-40.40%
1Y Return
-53.44%
Fundamentals
Market Cap ($ Mn)
166
PE Ratio
-
PB Ratio
5.78
PEG Ratio
-
ROE
-
ROCE
-29.67%
EPS (TTM)
$-0.13
Investment Returns
1 Week
32.44%
1 Month
52.82%
3 Months
-16.29%
6 Months
-40.40%
9 Months
-40.99%
Financials
Quarterly
All values in $ Mn
0.5
Mar 25
0.3
Jun 25
0.8
Sep 25
0.5
Dec 25
0.5
Mar 26
0.4
Jun 26
Updates
11Nov
Barclays raises Humacyte price target to $0.6, keeps equal-weight
Barclays raised Humacyte's price target from $0.5 to $0.6. Analyst Christopher Pasquale maintained an Equal-Weight rating. The new target represents a $0.1 increase over the previous estimate.
Yesterday
10Nov
BTIG reiterates Buy rating on Humacyte, maintains $2 price target
BTIG analyst Ryan Zimmerman reiterated a Buy rating on Humacyte. Price target maintained at $2 per share. Rating action indicates stable analyst outlook.
2 days ago
10Nov
Humacyte Synvest sales jump 151% to $1 million in Q3 2026
Synvest commercial sales rose 151% sequentially to over $1 million in Q3 2026. Hospital adoption increased 44%, growing from 34 to 49 accounts during the quarter. Net loss narrowed to $15.5 million from $17.5 million, driven by lower R&D spend. Cash position stands at $64.9 million with operating cash burn reduced to $15.0 million.
2 days ago
3Nov
Humacyte to present coronary vessel data at AHA Scientific Sessions
Humacyte Inc. presents at AHA Scientific Sessions from November 6–9, 2026. Focus is on investigational coronary tissue engineered vessel for CABG. Includes invited talk by CEO Laura Niklason and Phase 2a study design details. Preclinical data from porcine and ovine models to be shared.
9 days ago
15Oct
Humacyte sees 44% jump in hospitals ordering Symvess in Q3 2026
Hospitals ordering Symvess rose 44% in Q3 2026 to 49 facilities. Adoption grew from 34 hospitals at the end of Q2 2026. Ordering activity increased sequentially each month of the quarter. Surgeon case studies submitted indicate growing clinical engagement.
28 days ago
5Sep
KSF probes Humacyte officers after FDA Form 483 violations and lawsuit
KSF continues investigation into Humacyte officers over potential fiduciary breaches. FDA issued Form 483 citing lack of microbial testing and quality oversight. Securities class action lawsuit proceeds after court denies motion to dismiss. Investors urged to contact firm regarding legal rights without cost.
